Format

Send to

Choose Destination
See comment in PubMed Commons below
Se Pu. 2008 Sep;26(5):559-62.

[Resolution of thyroxine hormone enantiomers by precolumn derivatization with a fluorescent chiral reagent using reversed-phase high performance liquid chromatography].

[Article in Chinese]

Author information

1
Department of Chemistry, Science College of Yanbian University, Yanji 133002, China. jia_shaodong@yahoo.com.cn

Abstract

A highly fluorescent chiral tagging reagent, R(-)-4-(N,N-dimethylaminosulfonyl)-7-(3-isothiocy-anatopyrrolidino)-2,1,3-benzoxadiazole (R(-)-DBD-PyNCS), was employed for the enantiomer separation of thyroxine hormone, D,L-3,5,3',5'-tetraiodothyronine (T4) and L-3,5,3'-triiodothyronine (T3). The reaction of R(-)-DBD-PyNCS with the thyroxine enantiomers was carried out at 40 degrees C for 20 min under a basic medium surrounding to yield the corresponding pair of diastereomers. No racemization occurs during the tagging reaction under the optimized conditions. Various experimental parameters for the derivatization reaction including the concentration of tagging reagent, reaction temperature and reaction time have been studied in order to get the highest yield of T4/T3 derivatives. The structures of T4/T3 derivatives were identified based on high performance liquid chromatography-mass spectrometry (HPLC-MS) measurement in negative mode. The efficient separation of derivatives have been achieved by isocratic elution with a water-acetonitrile mobile phase containing 1% acetic acid in a reversed-phase column utilizing a conventional fluorescence detector. The calibration curves of L-T3, D,L-T4 were linear over the concentration ranges of 0.0067-0.22 microg/microL and 0.016-0.30 microg/microL, respectively. The limits of detection (S/N = 3) for L-T3 and D,L-T4 were 0.85 microg/mL and 0.02 microg/mL, respectively. The proposed method has been successfully applied to the determination of T3 and T4 in clinical pharmaceutics.

PMID:
19160753
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Loading ...
    Support Center